Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link BPC 157 Erectile Dysfunction Study: What the Evidence Actually Shows FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA's Overreach on Compounded Peptides